酶联免疫吸附法检测survivin在膀胱癌早期诊断中的临床价值

Clinical research of ELISA to detect survivin in the early diagnosis of bladder cancer

目的以尿脱落细胞学检查为对照,应用Western-blot检测证实survivin蛋白表达,了解酶联免疫吸附实验(ELISA)诊断膀胱肿瘤的可行性。方法对39例疑似膀胱肿瘤患者和39例正常成人行尿脱落细胞学检查和ELSIA检查,对切除的肿瘤组织标本行Western-blot检测。结果尿脱落细胞学检查敏感性为7.4%(2/27);ELISA的敏感性为58.3%(21/36),特异性为69.2%(27/39)。Western-blot和ELISA在膀胱肿瘤诊断的敏感性在G1级为77.8%(14/18)和68.4%(13/20),G2级为77.8%(7/9)和60%(6/10),G3级为50%(2/4)和20%(1/5)。3种检查方法的阳性率存在统计学差异(P<0.05),其中尿脱落细胞学检查阳性率为6.89%,ELISA检查方法的阳性率为53.8%,Western-blot检查的阳性率为73.5%。结论 ELISA法操作简单,但特异性与敏感性不高,且需要成批检测,不适合临床应用。

ObjectiveTo investigate the feasibility of enzyme linked immunosorbent assay （ELISA） in the diagnosis of bladder cancer. Methods Urine samples of 39 suspected bladder cancer cases and 39 health adults were detected by cytology and ELISA. The expression of survivin protein in bladder cancer was examined by Westernblot to validate the results of ELISA. ResultsThe sensitivity of urine cytology was 7.4% （2/27）. The sensitivity and specificity of ELISA was 58.3% （21/36） and 69.2% （27/39）. The sensitivity of Westernblot and ELISA were778% （14/18） and 68.4％（13/20） for G1 bladder tumors; 77.8％（7/9） and 60％（6/10） for G2 bladder tumors; 50％（2/4） and 20％（1/5） for G3 bladder tumors.There was significant difference between the three methods （P＜0.05）, the positive rate of urine exfoliative cytology was 6.89％, the positive rate of ELISA examination was 53.8％, the positive rate of Westernblot was 73.5％. ConclusionsELISA is simple to operate, but it has low sensitivity and specificity. Besides, it requires a large number of samples to be detected at the same time. Therefore, ELISA is not fit for clinical application.